Platelet Dysfunction, Traumatic Brain Injury
Conditions
Brief summary
This study evaluates the impact of platelet transfusion on geriatric patients with platelet dysfunction from Traumatic Brain Injury. The authors hypothesize that patients will recover better if their platelet dysfunction is corrected with platelet transfusion.
Detailed description
The geriatric population is subject to traumatic brain injury, often occurring as a result of falls. This patient population is also often receiving anticoagulants and platelet inhibitors increasing their risk of post-injury hemorrhage. Following Traumatic Brain Injury, even without platelet inhibitor medications, platelets become dysfunctional and are no longer able to assist with clot formation. Therefore risk of hemorrhage is increased, both in the brain, and other hemorrhagic sites. Clinical practice at Carolinas Medical Center is to transfuse platelets in patients with platelet dysfunction following brain injury. The current study is investigating the impact of transfusion on correction of platelet dysfunction and patient outcome. Furthermore, stored platelet dysfunction can be corrected by supplementation with cytochrome c, which supports mitochondrial function. Therefore, the ability of cytochrome c to correct dysfunction in ex vivo platelets from patients with Traumatic Brain Injury will be assessed.
Interventions
DIAGNOSTIC_TESTPlatelet mapping Thromboelastography
These diagnostic tests will be acquired in patients with brain injury, to determine prediction of clinical, functional and psychological outcome.
Sponsors
Carolinas Medical Center
Wake Forest University Health Sciences
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
55 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
Traumatic brain injury with Glasgow Coma Scale Score (GCS) \<=13
Exclusion criteria
Previously know coagulation dysfunction
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in platelet function | Within 5 hours | Correction of platelet inhibition measured before and after transfusion through platelet mapping thromboelastography |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mortality | 1-3 months | Mortality will be compared to admission platelet inhibition |
| Functional Independence Measure | 6-12 months | Patient function as measured by Functional Independence Measure compared to platelet inhibition |
Countries
United States
Outcome results
None listed